Inventor
STANGELAND ERIC
US20 patents
⚠️ This page may combine multiple inventors who share the name “STANGELAND ERIC”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
THERAVANCE INC
6 patentsUS7141671B2Nov 28, 2006
Biphenyl derivatives
THERAVANCE INC145 citations98
US7514558B2Apr 7, 2009
Biphenyl derivatives
THERAVANCE INC32 citations96
US7994209B2Aug 9, 2011
3-phenoxymethylpyrrolidine compounds
THERAVANCE INC14 citations92
US7879879B2Feb 1, 2011
Biphenyl derivatives
THERAVANCE INC19 citations92
US7728144B2Jun 1, 2010
Biphenyl compounds useful as muscarinic receptor antagonists
THERAVANCE INC20 citations92
US8013152B2Sep 6, 2011
Biphenyl compounds useful as muscarinic receptor antagonists
THERAVANCE INC3 citations62
VALO HEALTH INC
4 patentsUS11548886B2Jan 10, 2023
Monocyclic compounds useful as GPR120 modulators
VALO HEALTH INC4 citations73
US10865201B2Dec 15, 2020
Bicyclic compounds useful as GPR120 modulators
VALO HEALTH INC4 citations72
US12116362B2Oct 15, 2024
Monocyclic compounds useful as GPR120 modulators
VALO HEALTH INC0 citations61
US11919891B2Mar 5, 2024
Bicyclic compounds useful as GPR120 modulators
VALO HEALTH INC0 citations61
STANGELAND ERIC
3 patentsTHERAVANCE RESPIRATORY CO LLC
3 patentsUS10836744B2Nov 17, 2020
Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity
THERAVANCE RESPIRATORY CO LLC0 citations51
US10590107B2Mar 17, 2020
Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity
THERAVANCE RESPIRATORY CO LLC0 citations51
US10358433B2Jul 23, 2019
Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity
THERAVANCE RESPIRATORY CO LLC0 citations51